GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (NAS:IMMP) » Definitions » Gross Profit

Immutep (Immutep) Gross Profit : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 1988. Start your Free Trial

What is Immutep Gross Profit?

Immutep's gross profit for the three months ended in Dec. 2023 was $0.00 Mil. Immutep's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Immutep's gross profit for the three months ended in Dec. 2023 was $0.00 Mil. Immutep's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Immutep's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

Immutep had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Immutep Gross Profit Historical Data

The historical data trend for Immutep's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Gross Profit Chart

Immutep Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 5.17 - 0.12 -

Immutep Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immutep's Gross Profit

For the Biotechnology subindustry, Immutep's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immutep's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's Gross Profit distribution charts can be found below:

* The bar in red indicates where Immutep's Gross Profit falls into.



Immutep Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Immutep's Gross Profit for the fiscal year that ended in Jun. 2023 is calculated as

Gross Profit (A: Jun. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Immutep's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Immutep's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Immutep  (NAS:IMMP) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Immutep had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Immutep Gross Profit Related Terms

Thank you for viewing the detailed overview of Immutep's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Immutep (Immutep) Business Description

Traded in Other Exchanges
Address
264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.